$1.95
7.58% today
Nasdaq, Nov 06, 09:07 pm CET
ISIN
US45779A8466
Symbol
NSPR

InspireMD Inc Stock price

$2.11
-0.39 15.60% 1M
-0.49 18.85% 6M
-0.52 19.77% YTD
-0.29 12.08% 1Y
+1.03 95.37% 3Y
-3.10 59.52% 5Y
-669,372.89 100.00% 10Y
-437,497.89 100.00% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
-0.02 0.71%

Key metrics

Basic
Market capitalization
$88.0m
Enterprise Value
$68.7m
Net debt
positive
Cash
$19.4m
Shares outstanding
32.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.5 | 11.7
EV/Sales
9.7 | 9.1
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
77.1%
Return on Equity
-88.7%
ROCE
-174.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.1m | $7.5m
EBITDA
$-42.0m | $-46.5m
EBIT
$-42.3m | $-56.2m
Net Income
$-41.4m | $-28.6m
Free Cash Flow
$-31.2m
Growth (TTM | estimate)
Revenue
7.6% | 7.5%
EBITDA
-56.2% | -39.9%
EBIT
-56.0% | -67.9%
Net Income
-62.1% | 10.8%
Free Cash Flow
-67.8%
Margin (TTM | estimate)
Gross
21.1%
EBITDA
-593.9% | -616.8%
EBIT
-598.8%
Net
-585.6% | -379.0%
Free Cash Flow
-442.1%
More
EPS
$-0.8
FCF per Share
$-1.0
Short interest
0.3%
Employees
86
Rev per Employee
$80.0k
Show more

Is InspireMD Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

InspireMD Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a InspireMD Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a InspireMD Inc forecast:

Buy
88%
Hold
13%

Financial data from InspireMD Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7.07 7.07
8% 8%
100%
- Direct Costs 5.58 5.58
12% 12%
79%
1.49 1.49
5% 5%
21%
- Selling and Administrative Expenses 28 28
53% 53%
400%
- Research and Development Expense 16 16
52% 52%
219%
-42 -42
56% 56%
-593%
- Depreciation and Amortization 0.35 0.35
35% 35%
5%
EBIT (Operating Income) EBIT -42 -42
56% 56%
-598%
Net Profit -41 -41
62% 62%
-585%

In millions USD.

Don't miss a Thing! We will send you all news about InspireMD Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InspireMD Inc Stock News

Neutral
Seeking Alpha
2 days ago
InspireMD, Inc. ( NSPR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Marvin Slosman - President, CEO & Director Michael Lawless - Chief Financial Officer Shane Gleason - Chief Commercial Officer Conference Call Participants Webb Campbell Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentat...
Neutral
GlobeNewsWire
2 days ago
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue
Neutral
GlobeNewsWire
3 days ago
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention.
More InspireMD Inc News

Company Profile

InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Head office United States
CEO Marvin Slosman
Employees 86
Founded 2005
Website www.inspiremd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today